2017
DOI: 10.1016/j.clnesp.2017.04.004
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: SUMMARYBackground & aimsThe purpose of the study was to compare the effects of the parenteral emulsion SMOFlipid®, with 15% fish oil, with Clinoleic® on retinopathy of prematurity (ROP) and other morbidities and growth, and to compare their impact on longitudinal serum levels of fatty acids. Retinopathy of prematurity, other morbidity and growth were correlated with each parenteral lipid supplement.MethodsNinety infants born at gestational age <28 weeks were randomized to treatment with SMO-Flipid® or Clinolei… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
112
1
1

Year Published

2018
2018
2020
2020

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 89 publications
(118 citation statements)
references
References 42 publications
(46 reference statements)
4
112
1
1
Order By: Relevance
“…Of the 78 infants who completed the study, 37 were randomized to receive Clinoleic (Baxter Medical AB) and 41 to receive SMOFlipid (Fresenius Kabi) parenteral lipids (Figure ). Detailed clinical characteristics of the infants can be found elsewhere . The total volume of parenteral lipid solution and milk administered during the first 2 weeks of life is reported in Table .…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…Of the 78 infants who completed the study, 37 were randomized to receive Clinoleic (Baxter Medical AB) and 41 to receive SMOFlipid (Fresenius Kabi) parenteral lipids (Figure ). Detailed clinical characteristics of the infants can be found elsewhere . The total volume of parenteral lipid solution and milk administered during the first 2 weeks of life is reported in Table .…”
Section: Resultsmentioning
confidence: 99%
“…However, the potential benefits of parenteral lipid solutions containing fish oil, such as SMOFlipid (Fresenius Kabi) and Omegaven (Fresenius Kabi, Uppsala, Sweden), in neonates have been questioned . One concern is the high EPA content, which may increase circulating EPA levels far above what is physiological, with unknown consequences for infant health . We have previously reported that infants on SMOFlipid (Fresenius Kabi) exceeded the recommended intake of EPA by >100%, concomitant with a doubling of serum EPA levels at PNA 14 days compared with the levels at birth .…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…A number of clinical trials have been performed to compare lipid peroxidation/oxidative stress and/or DHA/EPA levels for parenteral nutrition with a composite lipid emulsion containing fish oil (ie, SMOF) with other lipid emulsions (olive oil/soybean oil or soybean oil alone; Table ) . These trials all show that neonates given composite lipid emulsions containing fish oil experience beneficial modulation of their fatty‐acid profiles and/or reduced oxidative stress/lipid peroxidation than when given other lipid emulsions.…”
Section: Clinical Trials In Neonatesmentioning
confidence: 99%